UY34840A - Vacuna de virus de schmallenberg (sbv), métodos de producción y sus usos - Google Patents

Vacuna de virus de schmallenberg (sbv), métodos de producción y sus usos

Info

Publication number
UY34840A
UY34840A UY0001034840A UY34840A UY34840A UY 34840 A UY34840 A UY 34840A UY 0001034840 A UY0001034840 A UY 0001034840A UY 34840 A UY34840 A UY 34840A UY 34840 A UY34840 A UY 34840A
Authority
UY
Uruguay
Prior art keywords
sbv
production methods
virus vaccine
schmallenberg virus
schmallenberg
Prior art date
Application number
UY0001034840A
Other languages
English (en)
Spanish (es)
Inventor
Nikolin Veljko
Stadler Konrad
Lischewski Axel
Brix Alexander
Jeffrey P Knittel
Katharina Hedwig Toepfer
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of UY34840A publication Critical patent/UY34840A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12061—Methods of inactivation or attenuation
    • C12N2760/12063—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
UY0001034840A 2012-06-01 2013-05-31 Vacuna de virus de schmallenberg (sbv), métodos de producción y sus usos UY34840A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12170631 2012-06-01
EP13157875 2013-03-05

Publications (1)

Publication Number Publication Date
UY34840A true UY34840A (es) 2013-12-31

Family

ID=48607368

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034840A UY34840A (es) 2012-06-01 2013-05-31 Vacuna de virus de schmallenberg (sbv), métodos de producción y sus usos

Country Status (17)

Country Link
US (2) US9370562B2 (enExample)
EP (1) EP2855513B1 (enExample)
JP (1) JP6250649B2 (enExample)
CN (1) CN104350066B (enExample)
AR (1) AR091240A1 (enExample)
AU (1) AU2013267453C1 (enExample)
BR (1) BR112014029515A2 (enExample)
CA (1) CA2872961A1 (enExample)
DK (1) DK2855513T3 (enExample)
EA (1) EA034543B1 (enExample)
ES (1) ES2617351T3 (enExample)
IN (1) IN2014DN08927A (enExample)
MX (1) MX363044B (enExample)
PL (1) PL2855513T3 (enExample)
SG (1) SG11201407619SA (enExample)
UY (1) UY34840A (enExample)
WO (1) WO2013181270A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6250649B2 (ja) 2012-06-01 2017-12-20 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ シュマレンベルクウイルス（ｓｂｖ）ワクチン、その製造方法及び使用
EP2855512B1 (en) 2012-06-01 2018-02-28 Boehringer Ingelheim Vetmedica GmbH Genomic sequences of schmallenberg virus and uses thereof
HK1216006A1 (zh) * 2013-03-12 2016-10-07 Boehringer Ingelheim Animal Health USA Inc. 反向遺傳學施馬倫貝格病毒疫苗組合物，和其使用方法
CN104232587B (zh) * 2014-09-02 2016-08-17 中国检验检疫科学研究院 稳定表达施马伦贝格病毒核衣壳蛋白的细胞系及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0811736B2 (ja) * 1986-08-07 1996-02-07 財団法人化学及血清療法研究所 牛流行熱・イバラキ病・アカバネ病３種混合不活化ワクチン
GB9110808D0 (en) 1991-05-17 1991-07-10 Retroscreen Ltd Aids vaccine and method for its production
US6114108A (en) 1995-08-29 2000-09-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of viral nucleic acids
US20080226682A1 (en) * 2007-03-13 2008-09-18 Peros Systems Technologies, Inc. Immunoactive Compositions for Improved Oral Delivery of Vaccines and Therapeutic Agents
EP2062594A1 (en) 2007-11-21 2009-05-27 Wyeth Farma, S.A. Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same
JP6250649B2 (ja) 2012-06-01 2017-12-20 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ シュマレンベルクウイルス（ｓｂｖ）ワクチン、その製造方法及び使用
EP2855512B1 (en) 2012-06-01 2018-02-28 Boehringer Ingelheim Vetmedica GmbH Genomic sequences of schmallenberg virus and uses thereof

Also Published As

Publication number Publication date
US9872897B2 (en) 2018-01-23
AU2013267453A1 (en) 2014-11-13
EP2855513A1 (en) 2015-04-08
ES2617351T3 (es) 2017-06-16
JP2015519367A (ja) 2015-07-09
JP6250649B2 (ja) 2017-12-20
EA201401352A1 (ru) 2015-05-29
CN104350066A (zh) 2015-02-11
AU2013267453B2 (en) 2017-04-06
US9370562B2 (en) 2016-06-21
EP2855513B1 (en) 2016-12-07
PL2855513T3 (pl) 2017-05-31
WO2013181270A1 (en) 2013-12-05
EA034543B1 (ru) 2020-02-19
DK2855513T3 (en) 2017-03-13
US20160250317A1 (en) 2016-09-01
AR091240A1 (es) 2015-01-21
BR112014029515A2 (pt) 2017-07-25
SG11201407619SA (en) 2014-12-30
US20130323277A1 (en) 2013-12-05
IN2014DN08927A (enExample) 2015-05-22
CN104350066B (zh) 2018-06-19
AU2013267453C1 (en) 2017-08-10
MX363044B (es) 2019-03-06
CA2872961A1 (en) 2013-12-05
MX2014014521A (es) 2015-02-24

Similar Documents

Publication Publication Date Title
UY34680A (es) Anticuerpos humanos anti-cd27, métodos, y usos
IL264454A (en) Novel compositions, uses and methods for making them
UY34885A (es) Proteínas de unión anti-mesotelina
CL2016002455A1 (es) Anticuerpos multiespecíficos.
UY34651A (es) ?formas de dosificación de liberación inmediata resistentes a la manipulación, procesos para prepararlas, métodos y usos de las mismas?..
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
DK3553177T3 (da) Benzylisoquinolinalkaloider (bia) som producerer mikrober, og fremgangsmåder til fremstilling og anvendelse deraf
UY34804A (es) Inhibidores del nampt
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
UY34674A (es) Cepa de flavobacterium plaguicida y composiciones bioactivas, metabolitos y usos
IL261314A (en) Process for pure carbon production, compositions, and methods thereof
MX2015011529A (es) Reordenamiento del virus de infuenza b.
MX2023006415A (es) Anticuerpos, usos y metodos.
FI20135605L (fi) Zeta-positiivinen hydrogenoitu nanotimanttijauhe, zeta-positiivinen hydrogenoitu nanotimanttidispersio, ja menetelmät niiden valmistamiseksi
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
DK3056272T3 (da) Betamolekylærsi, fremstillingsfremgangsmåde dertil og hydrogeneringskatalysator dermed
FR3026399B1 (fr) Grue, notamment grue-derrick
BR112015017420A2 (pt) recombinação de vírus influenza
UY34679A (es) ?PROCEDIMIENTO PARA OBTENER UNA COMPOSICIÓN DE IgG MEDIANTE TRATAMIENTO TÉRMICO?
UY34595A (es) Composición farmacéutica de liberación prolongada de trimetazidina
EP2807256A4 (en) MYONECTIN (CTRP15), COMPOSITION COMPRISING SAME AND METHODS OF USE
UY34840A (es) Vacuna de virus de schmallenberg (sbv), métodos de producción y sus usos
LT3155004T (lt) Vakcina, skirta asmeniui su sutrikusiu imunitetu